Do analysts prefer CASI or ASBP?

CASI Pharmaceuticals presently has a consensus target price of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe CASI Pharmaceuticals is more favorable than Aspire Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CASI or ASBP more profitable?

CASI Pharmaceuticals has a net margin of -183.93% compared to Aspire Biopharma's net margin of -11,362.21%. Company Net Margins Return on Equity Return on Assets CASI Pharmaceuticals -183.93% N/A -131.54% Aspire Biopharma -11,362.21% N/A -299.70%

Do analysts prefer CASI or QNRX?

CASI Pharmaceuticals currently has a consensus price target of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' higher probable upside, equities analysts clearly believe CASI Pharmaceuticals is more favorable than Quoin Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate OBSV or CASI?

CASI Pharmaceuticals has a consensus target price of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe CASI Pharmaceuticals is more favorable than ObsEva. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CASI Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

CASI Pharmaceuticals (CASI) Competitors

$0.21 0.00 (0.00%)

As of 08/13/2026

Compare

CASI vs. ASBP, QNRX, CNSP, OBSV, and LEXX

Should you buy CASI Pharmaceuticals stock or one of its competitors? CASI Pharmaceuticals's main competitors and comparable companies include Aspire Biopharma (ASBP), Quoin Pharmaceuticals (QNRX), CNS Pharmaceuticals (CNSP), ObsEva (OBSV), and Lexaria Bioscience (LEXX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does CASI Pharmaceuticals compare to Aspire Biopharma?

CASI Pharmaceuticals (NASDAQ:CASI) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

CASI Pharmaceuticals has a net margin of -183.93% compared to Aspire Biopharma's net margin of -11,362.21%.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
Aspire Biopharma	-11,362.21%	N/A	-299.70%

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by insiders. Comparatively, 5.8% of Aspire Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Aspire Biopharma had 2 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 2 mentions for Aspire Biopharma and 0 mentions for CASI Pharmaceuticals. Aspire Biopharma's average media sentiment score of 0.74 beat CASI Pharmaceuticals' score of 0.00 indicating that Aspire Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
Aspire Biopharma	Positive

CASI Pharmaceuticals has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, Aspire Biopharma has a beta of 0.11, indicating that its share price is 89% less volatile than the broader market.

CASI Pharmaceuticals presently has a consensus target price of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe CASI Pharmaceuticals is more favorable than Aspire Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aspire Biopharma has lower revenue, but higher earnings than CASI Pharmaceuticals. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than Aspire Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
Aspire Biopharma	$10K	1,020.50	-$24.48M	-$116.67	N/A

Summary

CASI Pharmaceuticals beats Aspire Biopharma on 10 of the 14 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to Quoin Pharmaceuticals?

CASI Pharmaceuticals (NASDAQ:CASI) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

Quoin Pharmaceuticals has lower revenue, but higher earnings than CASI Pharmaceuticals. Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by insiders. Comparatively, 11.2% of Quoin Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Quoin Pharmaceuticals has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%

In the previous week, Quoin Pharmaceuticals had 3 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 3 mentions for Quoin Pharmaceuticals and 0 mentions for CASI Pharmaceuticals. Quoin Pharmaceuticals' average media sentiment score of 0.62 beat CASI Pharmaceuticals' score of 0.00 indicating that Quoin Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
Quoin Pharmaceuticals	Positive

CASI Pharmaceuticals currently has a consensus price target of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' higher probable upside, equities analysts clearly believe CASI Pharmaceuticals is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

CASI Pharmaceuticals has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market.

Summary

CASI Pharmaceuticals beats Quoin Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to CNS Pharmaceuticals?

CASI Pharmaceuticals (NASDAQ:CASI) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

CNS Pharmaceuticals has lower revenue, but higher earnings than CASI Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A

22.2% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 21.2% of CASI Pharmaceuticals shares are owned by insiders. Comparatively, 0.0% of CNS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

CASI Pharmaceuticals has a beta of 0.91, suggesting that its share price is 9% less volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.05, suggesting that its share price is 205% more volatile than the broader market.

In the previous week, CNS Pharmaceuticals had 3 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 3 mentions for CNS Pharmaceuticals and 0 mentions for CASI Pharmaceuticals. CASI Pharmaceuticals' average media sentiment score of 0.00 beat CNS Pharmaceuticals' score of -0.07 indicating that CASI Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
CNS Pharmaceuticals	Neutral

CNS Pharmaceuticals has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
CNS Pharmaceuticals	N/A	-204.25%	-141.87%

CASI Pharmaceuticals currently has a consensus price target of $4.00, indicating a potential upside of 1,827.71%. CNS Pharmaceuticals has a consensus price target of $20.00, indicating a potential upside of 262.32%. Given CASI Pharmaceuticals' higher possible upside, equities research analysts plainly believe CASI Pharmaceuticals is more favorable than CNS Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

CASI Pharmaceuticals beats CNS Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to ObsEva?

ObsEva (NASDAQ:OBSV) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

17.5% of ObsEva shares are owned by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are owned by institutional investors. 14.4% of ObsEva shares are owned by insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

CASI Pharmaceuticals has higher revenue and earnings than ObsEva. CASI Pharmaceuticals is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A

CASI Pharmaceuticals has a consensus target price of $4.00, indicating a potential upside of 1,827.71%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe CASI Pharmaceuticals is more favorable than ObsEva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

ObsEva has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, CASI Pharmaceuticals has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

In the previous week, ObsEva's average media sentiment score of 0.00 equaled CASI Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
ObsEva	Neutral
CASI Pharmaceuticals	Neutral

ObsEva has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
CASI Pharmaceuticals	-183.93%	N/A	-131.54%

Summary

CASI Pharmaceuticals beats ObsEva on 9 of the 13 factors compared between the two stocks.

How does CASI Pharmaceuticals compare to Lexaria Bioscience?

CASI Pharmaceuticals (NASDAQ:CASI) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, risk, dividends, institutional ownership, earnings and profitability.

CASI Pharmaceuticals has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Lexaria Bioscience has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

22.2% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 21.2% of CASI Pharmaceuticals shares are held by company insiders. Comparatively, 8.4% of Lexaria Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Lexaria Bioscience has lower revenue, but higher earnings than CASI Pharmaceuticals. Lexaria Bioscience is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$26.85M	0.10	-$39.26M	-$3.01	N/A
Lexaria Bioscience	$710K	21.01	-$11.90M	-$5.10	N/A

In the previous week, Lexaria Bioscience had 4 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 4 mentions for Lexaria Bioscience and 0 mentions for CASI Pharmaceuticals. Lexaria Bioscience's average media sentiment score of 0.57 beat CASI Pharmaceuticals' score of 0.00 indicating that Lexaria Bioscience is being referred to more favorably in the news media.

Company	Overall Sentiment
CASI Pharmaceuticals	Neutral
Lexaria Bioscience	Positive

CASI Pharmaceuticals currently has a consensus price target of $4.00, suggesting a potential upside of 1,827.71%. Lexaria Bioscience has a consensus price target of $22.50, suggesting a potential upside of 148.89%. Given CASI Pharmaceuticals' higher possible upside, equities research analysts plainly believe CASI Pharmaceuticals is more favorable than Lexaria Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lexaria Bioscience has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -183.93%. CASI Pharmaceuticals' return on equity of 0.00% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-183.93%	N/A	-131.54%
Lexaria Bioscience	N/A	-174.93%	-143.89%

Summary

CASI Pharmaceuticals beats Lexaria Bioscience on 9 of the 14 factors compared between the two stocks.

Get CASI Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CASI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CASI vs. The Competition

Export

Metric	CASI Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.55M	$11.89B	$7.06B	$13.10B
Dividend Yield	N/A	2.70%	2.57%	10.45%
P/E Ratio	-0.07	640.15	211.09	21.74
Price / Sales	0.10	743.87	602.98	92.99
Price / Cash	N/A	66.45	70.48	50.90
Price / Book	1.73	11.60	12.91	6.24
Net Income	-$39.26M	$2.77B	$3.45B	$347.60M
7 Day Performance	N/A	0.17%	1.12%	1.07%
1 Month Performance	N/A	0.35%	1.79%	1.03%
1 Year Performance	-89.30%	161.52%	67.69%	20.77%

CASI Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CASI CASI Pharmaceuticals	N/A	$0.21 flat	$4.00 +1,827.7%	N/A	$2.55M	$26.85M	N/A	180	News Coverage
ASBP Aspire Biopharma	0.3843 of 5 stars	$7.04 -2.6%	N/A	-98.5%	$9.36M	$10K	N/A	N/A	Earnings Report
QNRX Quoin Pharmaceuticals	0.7363 of 5 stars	$4.35 -2.2%	N/A	-17.0%	$8.94M	N/A	N/A	4	News Coverage Earnings Report
CNSP CNS Pharmaceuticals	3.5756 of 5 stars	$5.36 -7.4%	$20.00 +273.1%	-23.5%	$8.46M	N/A	N/A	5	Earnings Report Upcoming Earnings
OBSV ObsEva	N/A	N/A	N/A	N/A	$7.94M	N/A	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CASI) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CASI Pharmaceuticals (CASI) Competitors

CASI vs. ASBP, QNRX, CNSP, OBSV, and LEXX

How does CASI Pharmaceuticals compare to Aspire Biopharma?

Summary

How does CASI Pharmaceuticals compare to Quoin Pharmaceuticals?

Summary

How does CASI Pharmaceuticals compare to CNS Pharmaceuticals?

Summary

How does CASI Pharmaceuticals compare to ObsEva?

Summary

How does CASI Pharmaceuticals compare to Lexaria Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CASI vs. The Competition

CASI Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CASI Pharmaceuticals (CASI) Competitors

CASI vs. ASBP, QNRX, CNSP, OBSV, and LEXX

How does CASI Pharmaceuticals compare to Aspire Biopharma?

Is CASI or ASBP more profitable?

Do insiders and institutionals believe in CASI or ASBP?

Does the media refer more to CASI or ASBP?

Which has more risk and volatility, CASI or ASBP?

Do analysts prefer CASI or ASBP?

Which has stronger earnings and valuation, CASI or ASBP?

Summary

How does CASI Pharmaceuticals compare to Quoin Pharmaceuticals?

Which has better valuation and earnings, CASI or QNRX?

Do insiders & institutionals believe in CASI or QNRX?

Is CASI or QNRX more profitable?

Does the media refer more to CASI or QNRX?

Do analysts prefer CASI or QNRX?

Which has more risk & volatility, CASI or QNRX?

Summary

How does CASI Pharmaceuticals compare to CNS Pharmaceuticals?

Which has preferable earnings and valuation, CASI or CNSP?

Do institutionals & insiders believe in CASI or CNSP?

Which has more volatility and risk, CASI or CNSP?

Does the media prefer CASI or CNSP?

Is CASI or CNSP more profitable?

Do analysts rate CASI or CNSP?

Summary

How does CASI Pharmaceuticals compare to ObsEva?

Do insiders & institutionals have more ownership in OBSV or CASI?

Which has higher valuation and earnings, OBSV or CASI?

Do analysts rate OBSV or CASI?

Which has more risk & volatility, OBSV or CASI?

Does the media favor OBSV or CASI?

Is OBSV or CASI more profitable?

Summary

How does CASI Pharmaceuticals compare to Lexaria Bioscience?

Which has more volatility and risk, CASI or LEXX?

Do institutionals and insiders hold more shares of CASI or LEXX?

Which has stronger valuation and earnings, CASI or LEXX?

Does the media refer more to CASI or LEXX?

Do analysts recommend CASI or LEXX?

Is CASI or LEXX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CASI vs. The Competition

CASI Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools